Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Next Previous
Trial Profile

Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketorolac/phenylephrine (Primary) ; Anti-inflammatories; Mydriatics
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 22 May 2015 According to a media release from the European Medicines Agency, Omidria [ketorolac/phenylephrine] has received a positive opinion for from the Committee for Medicinal Products for Human Use (CHMP) for maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement surgery.
    • 19 Apr 2013 The phase II and III data analyses will be included in both the US and European marketing applications for OMS 302, according to an Omeros media release.
    • 19 Apr 2013 Additional data from analyses of phase II and III trials will be presented at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress, according to an Omeros media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top